Literature DB >> 2912228

Systemic vascular autoregulation amplifies pressor responses to vasoconstrictor agents.

P J Metting1, P M Stein, B A Stoos, K A Kostrzewski, S L Britton.   

Abstract

Experiments were performed in seven conscious dogs to evaluate the contribution of total systemic autoregulation to the increase in mean arterial pressure (MAP) produced by the intravenous administration of pressor agents. Each dog was instrumented for the measurement of aortic pressure, central venous pressure, and cardiac output, and all dogs received hexamethonium to block autonomic ganglionic transmission. Angiotensin II (ANG II), arginine vasopressin (AVP), or norepinephrine (NE) were titrated over a 15- to 20-min period until MAP was increased to a new steady-state value approximately 50-55% above the normotensive control. Then while a constant infusion of the pressor agents was maintained, MAP was controlled via a gravity reservoir for 15-min periods at either the hypertensive value or at the animal's normotensive value. With all three pressor agents, total peripheral resistance (TPR) was greater when MAP was controlled at the hypertensive value than when the vasculature was protected from the elevated pressure by controlling MAP at the normotensive value. Thus a portion of the increase in TPR during the infusion of ANG II, AVP, or NE was due to autoregulatory-mediated vasoconstriction elicited by the increase in MAP. The fractions of the increases in TPR and MAP contributed by primary vasoconstriction vs. autoregulation were determined from the pressure-flow relationships. The pressure-induced increases in TPR accounted for 74% of the total increase in MAP produced by AVP, 62% of the pressor response to NE, and 34% of the response to ANG II. These results demonstrate that the direct vasoconstrictor effects of pressor agents can be significantly amplified by secondary autoregulatory responses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912228     DOI: 10.1152/ajpregu.1989.256.1.R98

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  Intermittent hypoxia in rats increases myogenic tone through loss of hydrogen sulfide activation of large-conductance Ca(2+)-activated potassium channels.

Authors:  Olan Jackson-Weaver; Daniel A Paredes; Laura V Gonzalez Bosc; Benjimen R Walker; Nancy L Kanagy
Journal:  Circ Res       Date:  2011-04-21       Impact factor: 17.367

2.  Constriction of retinal arterioles to endothelin-1: requisite role of rho kinase independent of protein kinase C and L-type calcium channels.

Authors:  Luke B Potts; Yi Ren; Guangrong Lu; Enoch Kuo; Ellen Ngo; Lih Kuo; Travis W Hein
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-17       Impact factor: 4.799

Review 3.  Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.

Authors:  Darcy Lidington; Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

4.  Constitutive smooth muscle tumour necrosis factor regulates microvascular myogenic responsiveness and systemic blood pressure.

Authors:  Jeffrey T Kroetsch; Andrew S Levy; Hangjun Zhang; Roozbeh Aschar-Sobbi; Darcy Lidington; Stefan Offermanns; Sergei A Nedospasov; Peter H Backx; Scott P Heximer; Steffen-Sebastian Bolz
Journal:  Nat Commun       Date:  2017-04-05       Impact factor: 14.919

5.  Experimental Subarachnoid Hemorrhage Drives Catecholamine-Dependent Cardiac and Peripheral Microvascular Dysfunction.

Authors:  Danny D Dinh; Darcy Lidington; Jeffrey T Kroetsch; Chloe Ng; Hangjun Zhang; Sergei A Nedospasov; Scott P Heximer; Steffen-Sebastian Bolz
Journal:  Front Physiol       Date:  2020-05-13       Impact factor: 4.566

6.  Sphingosine-1-Phosphate Signaling Regulates Myogenic Responsiveness in Human Resistance Arteries.

Authors:  Sonya Hui; Andrew S Levy; Daniel L Slack; Marcus J Burnstein; Lee Errett; Daniel Bonneau; David Latter; Ori D Rotstein; Steffen-Sebastian Bolz; Darcy Lidington; Julia Voigtlaender-Bolz
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.